ML22322A183
| ML22322A183 | |
| Person / Time | |
|---|---|
| Issue date: | 11/18/2022 |
| From: | Katherine Tapp Advisory Committee on the Medical Uses of Isotopes, NRC/NMSS/DMSST/MSEB |
| To: | |
| References | |
| Download: ML22322A183 (6) | |
Text
U.S. Nuclear Regulatory Commission (NRC)
Advisory Committee on the Medical Uses of Isotopes (ACMUI)
Subcommittee on Y-90 Microsphere Medical Events
Draft Report
Submitted on: November 18, 2022
Subcommittee Members Vasken Dilsizian, MD Josh Mailman Melissa Martin Michael OHara, PhD (Chair)
Megan Shober
Consultant to the Subcommittee: John F. Angle, MD NRC Staff Resource: Katie Tapp, PhD
Charge
The ACMUI Chair, Darlene Metter, MD, established this Subcommit tee on October 4, 2021 during the ACMUI 2021 Fall Meeting to evaluate the issue of Y-90 micro sphere medical events in more depth and, in consultation with the vendors, propose methods to decrease the number of Y-90 microsphere medical events.
Subcommittee Process
The subcommittee identified three factors which contributed to avoidable medical events (MEs):
- 1) low frequency of administration, 2) errors in treatment plan ning, and 3) workflow time challenges during the procedure that ensure that all elements o f the treatment are in accordance with the written directive. Based on these factors, the subcommittee proposes three actions to prevent future MEs.
The vendors that currently provide yttrium (Y)-90 microspheres in the United States (Boston Scientific and Sirtex Medical) were approached for their input on the proposed recommendations. The subcommittee received written and verbal i nput from both companies.
The Subcommittee concluded that implementing the proposed recom mendations would have a positive impact on radiation safety for microsphere users.
Subcommittee Recommendations The following recommendations can be used by the NRC and the ve ndors to serve as additional learning tools for licensees. The Subcommittee recommends that the NRC have additional conversations with the vendors to understand how the vendor pro grams impact MEs and issue an information notice to alert users to events that occurred in the past that could have been prevented by these measures. Furthermore, the NRC or the ACMUI should also consider publishing a journal article or give a presentation at a nation al meeting to reach licensees.
- 1. On a regular basis, licensees should review the mechanics of Y-90 microsphere delivery and setup procedures as described by the manufacturer.
- 2. Licensees should confirm all data and calculations in the tr eatment plan, prior to administration.
- 3. Licensees should use a time out to assure all elements of the administration are in accordance with the written directive. Elements such as conform ation of the patients name, treatment location and dosage comparison to the written d irective.
=
Background===
Hepatic radioembolization or selective internal radiation thera py (SIRT) is the intravascular administration of labeled glass or resin microspheres into the hepatic artery to deliver a radiation dose to a tumor target within the liver. Hepatic radioembolizat ion currently uses Y-90 labeled microspheres for the treatment of primary and metastatic malign ancies of the liver. Two vendors are currently approved by the U.S. Food and Drug Administration for treatment of liver tumors with Y-90 microspheres. TheraSphere TM from Boston Scientific is approved to treat hepatocellular carcinoma and SIR-Spheres from Sirtex Medical i s approved to treat metastatic colorectal tumors of the liver. During the past few years, both vendors have increased their hepatic radioembolization business by approximately twenty percent. Similar to past years, the MEs reported during 2020 were low compared to the number of tre atments performed.
The ACMUI Medical Events Subcommittee Report from October 2021 shows that MEs involving Y-90 administration continues to be the most common ME (Agencyw ide Documents Access and Management System Accession No. ML21288A127).
Radioactive Source Total ME over 4 Years Manual Brachytherapy 31 Remote Afterloader, Teletherapy, Gamma 41 Stereotactic unit Intravascular Cardiac Brachytherapy 5 Gamma Knife Perfexion + Icon 5 Y-90 Microspheres (combined) 93
The types of MEs for Y-90 microspheres included: >20% residual activity remaining in the delivery device, delivery device setup error, wrong dose given (treatment plan calculation error),
wrong site treated (catheter placement error), wrong dose vial selected and wrong site. In 2020, 80% of the MEs for TheraSphere TM and 100% for SIR-Spheres may have been influenced by infrequent performance of the treatment procedure and inattenti on during the procedure. A past ACMUI MEs Subcommittee noted that performance of a time out and use of a checklist immediately before administration of byproduct material could h ave prevented some MEs. The ME subcommittee proposed actions to prevent Y-90 microsphere ME s that included review the mechanics of Y-90 microsphere delivery devices and setup proced ures, confirm all data and calculations in the treatment plan and perform a time out at th e beginning of each procedure to assure all elements of the treatment are in accordance with the written directive. The ME subcommittee also proposed some possible elements of a time out that include identity of the patient via two identifiers (e.g., name and date of birth), pro cedure to be performed, isotope, activity, second check of dosage calculation and that the writt en directive and dosage to be delivered are identical as well ot her elements that may be applicable. In response, the NRC staff issued information notice 19-07, Methods to Prevent Medi cal Events, to inform licensees of these ACMUI recommendations ( ML19240A450).
Vendor Consultation Introduction
Addressing MEs involving the administration of Y-90 microsphere s may be facilitated by collaboration with vendors. The ACMUI created this subcommittee to evaluate this issue in conjunction with the vendors of Y-90 microspheres. There are cu rrently two Y-90 microsphere vendors in the United States, Boston Scientific (TheraSphere TM) and Sirtex Medical (SIR-Spheres). The subcommittee contacted both vendors for assistan ce with this evaluation. Both vendors were given copies of the MEs Committee report presented at the ACMUI meeting on October 4, 2021, general questions to start the conversation, a nd the ACMUIs proposed three actions to prevent Y-90 microsphere MEs. The vendors were speci fically asked if these proposed actions to prevent Y-90 microsphere MEs are appropriat e and if there are further actions that will help to reduce the number of MEs. Teleconfere nces were held on April 20, 2022, with Sirtex Medical and on May 26, 2022, with Boston Scie ntific.
Sirtex Medical
Sirtex Medical has developed programs and taken steps that they believe will reduce MEs and increase the safe and effective use of SIR-Spheres. In respons e to the Y-90 Microspheres Subcommittees request, Sirtex Medical evaluated the MEs report ed by licensees between 2017-2020 described in the 2021 ME Subcommittee report. Their e valuation identified four causes of MEs associated with SIR-Spheres, which were:
- 1. Greater than 20% residual activity remaining in the delivery device not due to stasis,
- 2. The wrong dose given (treatment plan calculation error),
- 3. The wrong site treated (catheter placement error), and
- 4. The wrong site (written directive error).
Sirtex Medical agreed that greater use of the ACMUI recommendat ions 1-3 by licensees may prevent MEs related to licensee set up of the device and proced ural errors.
One action the vendor has taken to prevent MEs was to develop a SIR-Spheres Microspheres Activity Calculator. This may serve as second check against the activity identified in the written directive. The accuracy of these types of spreadsheet calculato rs should be confirmed by Sirtex Medical, tested by licensees and reviewed by the Medical Team at the NRC.
Another action the vendor mentioned was the SIR-Spheres Traini ng Evaluation Certification Program. This purpose of this program is to ensure that Sirtex Medicals Y-90 microspheres licensees have the infrastructure in place to use radioactive m icrospheres. This program includes guidance that all necessary nuclear medicine and radia tion safety support equipment and personnel are in place and the licensee has sufficient arte riography capabilities. It also includes In-Service site visits from Sirtex Medicals multidisciplinary team for assistance with all of microsphere implantation components and training of the trea tment physician and radiation safety officer. In addition, the vendor cited that the vendor proctors assessment is another action to prevent MEs. The proctor can recommend additional pro ctoring sessions for treating physicians and institutions before being qualified by Sirtex to use SIR-Spheres. There is also a minimum frequency of treatments with SIR-Spheres necessary for continued SIR-Spheres use according to the vendor. Sirtex Medical has also increased the case coverage in their Supplemental Training program to combat MEs by putting more of the vendors experienced staff in closer contact with the users of their Y-90 microspher es.
Further Discussion with Sirtex Medical Further discussion between Sirtex Medical and the Medical Team at the NRC is necessary to further understand how Sirtex Medicals programs outlined here affect MEs, how the vendor judges the effectiveness of these programs and how the vendor t ests the accuracy of spreadsheet tools to calculate activity. After reviewing the ME events report for 2021 (ML22112A104) from the Medical Radiation Safety Team at NRC, the vendor ide ntified clogged microcatheters as approximately 30% of the MEs. In addition, th e NRC staff should understand the steps, if any, that the vendor is taking to limit the impac t of clogged microcatheters.
Boston Scientific
Boston Scientific has developed programs and products that they believe will reduce MEs and increase safe and effective use of TheraSphere TM. The vendors post market surveillance program monitors all complaints and responds when a potential t rend emerges. This review process includes reviewing the NRC database for TheraSphere TM related MEs to determine the root cause of the medical event and take action to minimize its frequency and severity.
In response to the Y-90 Microspheres Subcommittees request, Bo ston re-analyzed the 59 MEs NRC identified from 2017 to 2020. They calculated the rate of N RC reported MEs per volume of dose vials shipped within each year and identified the rate of reported MEs is much less than one percent of volume of dose vials shipped. In addition, the r ate of MEs has decreased during this time when compared to the increase in volume of dose vials shipped.
The vendor pointed to possible actions while responding to the questions that the Subcommittee used to open the discussion. Many of these actions the licensee already has at their disposal.
For example, leaving >20% volume of TheraSphere TM in the delivery device may need improved quality systems or events related to the delivery device may ne ed enhancements to the written directive and/or increased familiarization with the device. Sof tware tools or checklists could be used to improve issues like the wrong dose given due to calcula tion errors, catheter placement errors or selection of the wrong dose vial. Greater use of the ACMUI proposed actions to prevent MEs will also possibly reduce these issues.
Boston Scientific provides resources to aid in the planning and facilitation of TheraSphere TM Y-90 treatments. The resources include the TheraSphere TM Instructions for Use which is supported by training at new sites for physician authorized use rs, radiation safety officers and support staff and software tools to assist customers in treatme nt planning and ordering TheraSphereTM. The software tools include: TheraSphere TM Now, TheraSphereTM Treatment Window Illustrator, and TheraSphere TM iDOC.
TheraSphereTM Now is an online ordering tool that notifies users of potentia l order errors at the time of the order. The vendor informed the Subcommittee that ap proximately 50% of TheraSphereTM users currently use this tool.
TheraSphereTM Treatment Window Illustrator is a spreadsheet-based tool that can assist users with ordering the appropriate dose size based upon the desired absorbed dose, timing of administration, lung shunt fraction, dose to the lungs, and ant icipated residual waste.
TheraSphereTM iDOC is an online interactive dose ordering calculator that ca n assist users in calculating and ordering the appropriate TheraSphere TM dose vial size.
The optional TheraSphereTM Administration Checklist instructs users to confirm patient id entity, instructions for administration set priming, dose vial preparat ion, administration set assembly with the dose vial, final assembly immediately before administr ation, TheraSphere administration and disassembly and cleanup. The vendor believes appropriate use all these tools could reduce MEs.
Further Discussion with Boston Scientific
Further discussion between Boston Scientific and the Medical Te am at the NRC is necessary to fully understand how the vendors programs outlined here affect MEs, how the vendor judges the effectiveness of these programs and how the vendor tests th e accuracy of spreadsheet and software tools. Specifically, are MEs lower at licensed facilit ies that use Boston Scientifics spreadsheet/ software tools? In addition, the NRC staff should understand the steps the vendor is taking, if any, to limit the impact of clogged microcatheter s.
Summary The vendors have embraced the ACMUI proposed actions to prevent Y-90 MEs. However, the vendors should include these actions in their training of new u sers, interactions with current users and in discussion of MEs with any user. The Subcommittee believes that the NRC should embrace these three proposed actions to prevent Y-90 MEs to ens ure that all Y-90 microsphere users are aware of their utility.
The use of spreadsheets, checklists, and software tools appear to be methods the vendors have employed to reduce errors in Y-90 isotope ordering, selection o f the wrong dose vial, calculation errors, and to reduce the errors during Y-90 procedures. These tools can assist the end user to order Y-90 and properly administer the therapy. The accuracy of these tools is unclear and should be investigated more fully.
Recommendations The NRC should evaluate the utility of the software programs an d checklists provided by the microsphere vendors. A regular review of these tools can improv e the licensees understanding of these software devices, assist vendors with further developm ent of these tools, and potentially catch inconsistencie s between vendors and with NRC regulations and recommendations.
In addition, the NRC should issue information notices to alert licensees of MEs and, where possible, make recommendations and suggest measures licensees c an take to prevent similar events in the future. These recommendations can be used by the NRC and the vendors to serve as additional learning tools to prevent MEs.
In summary, the three recommendations for licensees are as foll ows:
- 1. On a regular basis, licensees should review the mechanics of Y-90 microsphere delivery and setup procedures as described by the manufacturer.
- 2. Licensees should confirm all data and calculations in the tr eatment plan, prior to administration.
- 3. Licensees should use a time out to assure all elements of the administration are in accordance with the written directive. Elements such as conform ation of the patients name, treatment location and dosage comparison to the written d irective.
References January 24, 2022, Email to Boston Scientific
January 24, 2022, Email to Sirtex Medical
April 20, 2022, 35.1000 Y-90 Microsphere Medical Event Review b y Sirtex Medical March 23, 2022, letter to Michael OHara from Boston Scientific
April 20, 2022, Presentation entitled 35.100 Y-90 Microsphere Medical Events Review from Sirtex Medical
Respectfully submitted,
Subcommittee on Y-90 Microsphere Medical Events Advisory Committee on the Medical Uses of Isotopes U.S. Nuclear Regulatory Commission